Search
Search
About
Log in
Join
Experiences with
Lupkynis
Posts
Communities
6 public posts
Filter results
Lupkynis protects kidneys in lupus nephritis patients for up to 3 years
However, eGFR didn’t decline as much in the
Lupkynis
group as it did in the placebo group. This meant that over the two years of AURORA 2, kidney function was protected in the
Lupkynis
group, but worsened in the placebo group.
However, eGFR didn’t decline as much in the
Lupkynis
group as it did in the placebo group. This meant that over the two years of AURORA 2, kidney function was protected in the
Lupkynis
group, but worsened in the placebo group.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
10 months ago
Lupkynis helps protect kidneys with lupus nephritis and high proteinuria
A significantly greater proportion of
Lupkynis
-treated patients achieved CRR after a year of treatment (41%) compared with the placebo group (21.9%), with a nearly 2.5 times higher odds of achieving a response on
Lupkynis
.
A significantly greater proportion of
Lupkynis
-treated patients achieved CRR after a year of treatment (41%) compared with the placebo group (21.9%), with a nearly 2.5 times higher odds of achieving a response on
Lupkynis
.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
11 months ago
Lupkynis approved in Switzerland to treat adults with lupus nephritis
“We are extremely pleased with the Swissmedic approval of
Lupkynis
for adults with lupus nephritis.
“We are extremely pleased with the Swissmedic approval of
Lupkynis
for adults with lupus nephritis.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
1 year ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Lupkynis Approved in UK to Treat Adults With Active Lupus Nephritis
“The MHRA authorization of
Lupkynis
for individuals with lupus nephritis in Great Britain, on the heels of the marketing authorization in the EU, further expands the availability of
Lupkynis
as a treatment option for people with lupus nephritis,” said Peter Greenleaf, president and CEO of Aurinia, in
“The MHRA authorization of
Lupkynis
for individuals with lupus nephritis in Great Britain, on the heels of the marketing authorization in the EU, further expands the availability of
Lupkynis
as a treatment option for people with lupus nephritis,” said Peter Greenleaf, president and CEO of Aurinia, in
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
1 year ago
2 New Meds Found to Completely Change Lupus Nephritis Treatment
has generally had a better steroid-sparing profile than
Lupkynis
.
has generally had a better steroid-sparing profile than
Lupkynis
.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
1 year ago
European Commission OKs Lupkynis for Active Lupus Nephritis
Lupkynis
’ approval was supported by data from a Phase 3 trial called AURORA (NCT03021499). The study enrolled 358 adults ages 18–75 with active lupus nephritis. Participants were assigned randomly to take
Lupkynis
or a placebo for about one year.
Lupkynis
’ approval was supported by data from a Phase 3 trial called AURORA (NCT03021499). The study enrolled 358 adults ages 18–75 with active lupus nephritis. Participants were assigned randomly to take
Lupkynis
or a placebo for about one year.
lupus-support1
Administrator
in
LUpus Patients Understanding and Support
2 years ago
Filter results
Clear filters
Posted in
All communities
LUpus Patients Understanding and Support
6 results
Sort by
Most Relevant
Newest